Management of severe refractory thrombocytopenia in dengue hemorrhagic fever with intravenous anti-D immune globulin

Pediatric Hematology and Oncology

Volumn 28, Issue 8, 2011, Pages 727-732

  Kharya, Gaurav ^a   Yadav, Satya Prakash ^a   Katewa, Satyendra ^b   Sachdeva, Anupam ^a  

^a SIR GANGA RAM HOSPITAL   (India)

^b Dr BL Kapoor Memorial Hospital   (India)

Author keywords

Dengue hemorrhagic fever; IV anti D; Thrombocytopenia

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; FRESH FROZEN PLASMA; HEMOGLOBIN; KAMRHO D; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RHESUS D ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; CHILL; CLINICAL ARTICLE; CRYOPRECIPITATE; DENGUE; DRUG FEVER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LENGTH OF STAY; LUNG HEMORRHAGE; MALE; PRESCHOOL CHILD; REFRACTORY THROMBOCYTOPENIA; RETROSPECTIVE STUDY; SCHOOL CHILD; STEROID THERAPY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENGUE HEMORRHAGIC FEVER; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; RHO(D) IMMUNE GLOBULIN; THROMBOCYTOPENIA;

EID: 80055019048     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.609581     Document Type: Article

References (17)

1. Gubler DJ, ClarkGG.Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis. 1995;1:55-57.
2. WHO. Dengue and Dengue Haemorrhagic Fever. Fact SheetNo. 117, revisedMay 2008.Geneva:World Health Organization; 2008.
3. Nimmannitya S.Denguehemorrhagic fever:disorders of hemostasis. In: EducationBook, IXCongress of the International Society of Haematology Asia-Pacific Division; Bangkok; October 24-28, 1999. International Society of Haematology, Asia-Pacific Division, pp. 184-187.
4. Saito M, Oishi K, Inoue S, et al. Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol. 2004;138:299-303. (Pubitemid 39472447)
5. Mitrakul C. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg. 1979;26:975-984.
6. Boonpucknavig S. Demonstration of dengue antibody complexes on the surface of platelets from patients with dengue hemorrhagic fever. Am J TropMed Hyg. 1979;28:881-884. (Pubitemid 10244410)
7. McMillan R. Chronic idiopathic thrombocytopenic purpura.N Engl J Med. 1981;304:1135-1147. (Pubitemid 11099209)
8. Cines DB. Immune thrombocytopenic purpura.N Engl J Med. 2002;346:995-1008.
9. Muller-Eckhardt C. The clinical significance of platelet associated IgG: a study on 298 patients with various disorders. Br J Haematol. 1980;46:123-131.
10. Kularante SAM, Walathara C, Mahindawansa SI, et al. Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study. Postgrad Med J. 2009;85:525-529.
11. Dimaano ME, Saito M, Honda S, et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg. 2007;77:1135-1138. (Pubitemid 351837807)
12. Yadav SP. What else can be done other than vector control to reduce mortality due to Dengue hemorrhagic fever (DHF)? BMJ. 2006. Available at: http://www.bmj.com/content/333/7572/773.4/reply.
13. De Castro RA, de Castro JA, Barez MY, et al. Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration anti D (Rh-D) antiglobulin.AmJTropMedHyg. 2007;76:737-742. (Pubitemid 351627718)
14. Yadav SP, Sachdeva A, Kharya G, et al. Control of massive bleeding in dengue hemorrhagic fever with severe thrombocytopenia by use of intravenous anti-D globulin. Pediatr Blood Cancer. 2008;51:812-813.
15. British Committee for Standards in Haematology. Guidelines for the use of Platelet Transfusions. Br J Haematol. 2003;122:10-23.
16. Makroo RN, Raina V, Kumar P, et al. Role of platelet transfusion in the management of dengue patients in a tertiary care hospital. Am J Transf Sci. 2007;1:4-7.
17. Scaradavou A,WooB,WoloskiBM, et al. Intravenous anti-D treatment ofimmune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689-2700. (Pubitemid 27172553)